Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/2/2016
Contact:Introgen Therapeutics, Inc.
Email:clinicaltrials@introgen.com
Phone:866.631.4646

Use our guide to learn which trials are right for you!

There is a need for more treatment options for patients with recurrent squamous cell cancer
of the head and neck (SCCHN). These tumors usually have a variety of genetic defects that
include disruption of the p53 pathway, a pathway that would ordinarily work to prevent the
development of tumors. In this study the transfer of the p53 gene to tumor cells using a
modified adenovirus (INGN 201) will be compared to methotrexate in patients who have failed
surgery, radiotherapy and chemotherapy with platinum or taxanes.


- 18 years or older

- Not eligible for surgery

- Must have had radiation and chemotherapy treatments

- No prior methotrexate treatments
We found this trial at
5
sites
Aurora, Colorado 80045
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Baltimore, Maryland 21204
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Columbia, South Carolina 29209
?
mi
from
Columbia, SC
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Louisville, Kentucky 40202
?
mi
from
Louisville, KY
Click here to add this to my saved trials